目的 分析老年肌层浸润性膀胱癌(MiBC)患者保留膀胱术后存活情况及影响因素。方法 采集2015年7月—2019年8月62例行保留膀胱术的老年MiBC患者的临床资料,统计患者术后1年内存活情况,并收集患者基线资料,包括年龄、临床分期、肿瘤数目、手术方式、术后膀胱灌注化疗、血清趋化因子配体5(CXCL5)水平,分析老年MiBC切除术后病死的影响因素。结果 62例老年MiBC患者保留膀胱术后1年病死11例,病死率17.74%。经Cox回归分析结果显示,CXCL5水平高、临床分期(T4期)均可能是老年MiBC患者术后病死的影响因素(P<0.05)。结论 老年MiBC保留膀胱术后具有一定的病死风险,且临床分期高、CXCL5水平高均为其发生的影响因素,临床可据此进行合理干预,以延长患者生存期。
Objective To analyze the survival and its influencing factors of elderly patients with muscle-invasive bladder cancer (MiBC) after bladder sparing surgery. Methods The clinical data of 62 elderly MiBC patients who underwent bladder sparing surgery from July 2015 to August 2019 were collected, and their one-year survival was calculated. Their baseline data were also collected including age, clinical stage, number of tumor, operation method, postoperative bladder perfusion chemotherapy, and serum chemokine ligand 5 (CXCL5) level, and the influencing factors of mortality after MiBC resection in the elderly were analyzed. Results Among the 62 elderly MiBC patients, 11 cases died one year after bladder sparing surgery, with the mortality rate of 17.74%. The results of Cox regression analysis showed that a high clinical stage (T4) and a high level of CXCL5 were the influencing factors of mortality in elderly patients with MiBC (P<0.05). Conclusion There is a risk of mortality in elderly MiBC patients after bladder sparing surgery, and a high clinical stage and a high level of CXCL5 are the influencing factors, which can be taken into consideration to conduct reasonable interventions to prolong the survival of patients.
[1] 李绍林,修有成,刘赞.肌层浸润性膀胱癌治疗的研究进展[J].医学综述,2018,24(5):85-89.
[2] 潘家波. 保留膀胱术后综合治疗肌层浸润性膀胱癌的临床疗效[J].中国急救医学,2017,37(2):88-89.
[3] 王淇超,曹敬毅,关升.经尿道膀胱肿瘤电切术治疗肌层浸润性膀胱癌预后影响因素分析[J].临床泌尿外科杂志,2015,30(9):819-822.
[4] 那彦群,叶章群,孙颖浩.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2014:36-37.
[5] 江方波,李发根.选择性膀胱部分切除术联合膀胱灌注化疗治疗肌层浸润性膀胱癌疗效及预后影响因素[J].国际泌尿系统杂志,2015,35(6):801-804.
[6] 赵仕佳,叶向东,肖成林.血清CXCL5水平与原发性肌层浸润性膀胱癌外科治疗后复发的相关性研究[J].医学临床研究,2017,34(11):2217-2219.
[7] 宋广智,袁海霞.血清趋化因子配体5预测膀胱癌外科治疗后复发的价值[J].实用临床医药杂志,2017,21(17):22-25.
[8] 吴丽媛,杨飞亚.趋化因子在膀胱癌诊断中作用的研究进展[J].临床泌尿外科杂志,2018,33(6):497-501.